145720.KO Dentium
- Market cap
- KRW 331B
- P/E
- 10.9x
- P/B
- 0.55x
- ROE
- 10.4%
- Dividend yield
- 1.56%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 145720.KO undervalued?
Graham number145720.KO trades 48.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dentium fundamental analysis
No fundamental analysis for Dentium yet.
Dentium stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dentium
Dentium CO., LTD manufactures and sells dental medical instrument worldwide. Its implant systems include superline, implantium, implantium 2, N.R. line, simple line 2, and slim line. The company also provides block and coloring; regeneration products; and digital dentistry products. In addition, it offers orthodontics, bright resin, tooth care, and other dental products. The company was formerly known as Biostech Co., Ltd. and changed its name to Dentium Co.,Ltd. in August 2…
Full company profileDentium financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dentium annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 120B | 151B | 186B | 253B | 230B | 292B | 356B | 393B | 408B | 346B | 321B |
| Gross Profit | 83.3B | 107B | 131B | 168B | 143B | 193B | 261B | 279B | 260B | 218B | 225B |
| Operating Income | 28.5B | 41.1B | 42.0B | 44.7B | 39.6B | 70.2B | 126B | 138B | 98.5B | 64.1B | 61.1B |
| EBITDA | - | 41.2B | 48.4B | 52.1B | 48.9B | 94.0B | 144B | 163B | 127B | 59.0B | 118B |
| Net Income | 19.8B | 30.1B | 34.3B | 14.8B | 22.5B | 55.5B | 86.1B | 96.5B | 72.7B | 16.4B | 62.2B |
| EPS | - | 3,486 | 3,972 | 1,714 | 2,614 | 6,434 | 9,980 | 11,193 | 8,431 | 1,903 | 7,215 |
| Balance Sheet | |||||||||||
| Total Assets | 187B | 311B | 437B | 547B | 510B | 570B | 675B | 774B | 894B | 933B | 987B |
| Total Liabilities | 118B | 148B | 242B | 341B | 282B | 279B | 301B | 310B | 341B | 372B | 392B |
| Shareholders' Equity | 69.0B | 162B | 194B | 207B | 229B | 292B | 374B | 465B | 555B | 562B | 596B |
| Cash & Short-term Investments | 9.06B | 53.2B | 21.8B | 28.1B | 37.3B | 65.8B | 72.1B | 86.9B | 99.6B | 77.1B | 62.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 17.6B | 21.7B | -575M | -11.6B | 75.8B | 74.1B | 47.0B | 65.0B | 36.5B | 13.2B | 60.9B |
| Capital Expenditure | 19.0B | 72.3B | 107B | 51.3B | 8.62B | 28.2B | 54.1B | 44.1B | 21.7B | 53.6B | 51.0B |
| Free Cash Flow | - | -51.4B | -109B | -64.1B | 66.7B | 45.1B | -7.10B | 20.8B | 14.8B | -40.3B | 9.86B |
| Ratios | |||||||||||
| ROE | 28.7% | 18.6% | 17.6% | 7.1% | 9.8% | 19.0% | 23.0% | 20.8% | 13.1% | 2.9% | 10.4% |
| ROA | 10.6% | 9.7% | 7.8% | 2.7% | 4.4% | 9.7% | 12.8% | 12.5% | 8.1% | 1.8% | 6.3% |
| Net Profit Margin | 16.5% | 20.0% | 18.4% | 5.9% | 9.8% | 19.0% | 24.2% | 24.5% | 17.8% | 4.7% | 19.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Dentium dividends
- Dividend yield
- 1.56%
- Forward dividend
- 600.00 KRW
- Payout ratio
- 31.5%
- Ex-dividend date
- Mar 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 5.17B | 600 | 31.5% |
| 2024 | KRW 3.45B | 400 | 4.7% |
| 2023 | KRW 2.59B | 300 | 2.7% |
| 2022 | KRW 2.16B | 250 | 2.5% |
| 2021 | KRW 1.72B | 200 | 3.1% |
| 2020 | KRW 1.72B | 200 | 7.7% |
| 2019 | KRW 1.29B | 150 | 8.7% |
| 2018 | KRW 1.29B | 150 | 3.8% |
| 2017 | KRW 608M | 70 | 2.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Dentium
- Insiders 24.38%
- Institutions 25.39%
- Public & others 50.23%
- Shares outstanding 8.26M
- Free float 5.27M
Dentium company profile
- Company name
- Dentium
- Ticker
- 145720.KO
- ISIN
- KR7145720009
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 849
- Fiscal year end
- December
- Address
- 21, Teheran-ro 87-gil, Seoul, South Korea
- Phone
- 82 70 7098-7535
- Website
- dentium.co.kr
About Dentium
Dentium CO., LTD manufactures and sells dental medical instrument worldwide. Its implant systems include superline, implantium, implantium 2, N.R. line, simple line 2, and slim line. The company also provides block and coloring; regeneration products; and digital dentistry products. In addition, it offers orthodontics, bright resin, tooth care, and other dental products. The company was formerly known as Biostech Co., Ltd. and changed its name to Dentium Co.,Ltd. in August 2002. Dentium Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.